Wet AMD

>

Latest News

Image credit: ©kwanchaift – stock.adobe.com
Alvotech announces positive top-line results for AVT06, a proposed biosimilar to aflibercept

January 3rd 2024

This study compared AVT06 with aflibercept (Eylea) in patients with neovascular AMD.

AAO 2023: Adverum Biotechnologies unveils 3-Year efficacy, safety results from OPTIC extension study in patients with wet AMD
AAO 2023: Adverum Biotechnologies unveils 3-Year efficacy, safety results from OPTIC extension study in patients with wet AMD

November 5th 2023

Image credit: ©MargJohnsonVA – stock.adobe.com
Vitreous Retina Macula Consultants of New York (VRMNY) to participate in a wet AMD study with Regenxbio

October 19th 2023

Retina Society 2023: A comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib, and sunitinib
Retina Society 2023: A comparison of the antiangiogenic profile of tyrosine kinase inhibitors vorolanib, axitinib, and sunitinib

October 16th 2023

Image credit: ©gopixa– stock.adobe.com
UC Davis researchers administer Phase 3 ABBV-RGX-314, a gene therapy treatment for wet AMD

September 5th 2023

Video Series
Video Interviews

More News

© 2024 MJH Life Sciences

All rights reserved.